摘要
目的研究胶质瘤Hsp70-肽复合物激活的T淋巴细胞抗肿瘤效应、探讨其用于临床治疗的可行性。方法取胶质瘤手术标本,经组织块法培养、建株胶质瘤细胞,冻融法获取胶质瘤细胞抗原,抗原与Hsp70体外构建Hsp70-肽复合物并激活T淋巴细胞,制备特异性CTL,MTT法检测对胶质瘤细胞的体外杀伤作用。结果Hsp70-肽复合物激活CTL对胶质瘤细胞的杀伤活性明显高于未经胶质瘤抗原激活的CTL对胶质瘤细胞的杀伤作用(P<0.01)。结论肿瘤组织中或细胞中提取的Hsp70-肽复合物作用于T淋巴细胞,能诱导CTL在体外对胶质瘤细胞能产生高效而特异杀伤作用,为临床制备肿瘤疫苗奠定理论基础。
Objective. To investigate the anti-tumor effect of T lymphocytes activated by Hsp70- peptide compound with glioma and the feasibility of clinical application. Methods： The glioma specimen were obtained in the surgery, the glioma cells were prepared by explant technique, the glioma cell antigen was obtained by freezing and thawing method, the Hsp70- peptide compound was constructed with antigen and Hsp70 in vitro, and then T lymphocyte was activated by the compound, special CTL was constructed, the killing effect on glioma cell was measured with MTT method in vitro. Results： The killing effect of CTL activated by Hsp70- peptide compound with Glioma was much higher than that of CTL without activated （P 〈 0.01）. Conclusion： The Hsp70- peptide compound with glioma could the special killing effect of CTL on glioma cell in vitro.
出处
《井冈山大学学报（自然科学版）》
2010年第2期75-77,共3页
Journal of Jinggangshan University (Natural Science)
